Table 2 Risk factor for recurrent VTE
Variables | Univariable analysis HR, 95% CI | p-value | Multivariable analysis 1 HR, 95% CI | p-value | Multivariable analysis 2 HR, 95% CI | p-value |
|---|---|---|---|---|---|---|
Age range (years) | ||||||
≤ 50 | Ref. | Ref. | Ref. | |||
]50–65] | 1.9 (1.3–2.7) | < 0.001 | 1.6 (1.1–2.3) | 0.020 | 1.6 (1.1–2.3) | 0.019 |
> 65 | 2.4 (1.8–3.3) | < 0.001 | 2.1 (1.5–3.0) | < 0.001 | 2.2 (1.5–3.0) | < 0.001 |
BMI range (kg/m2) | ||||||
≤ 25 | Ref. | Ref. | Ref. | |||
]25–30] | 1.1 (0.8–1.5) | 0.48 | 0.9 (0.7–1.2) | 0.58 | 0.9 (0.7–1.3) | 0.69 |
]30–35] | 1.1 (0.7–1.6) | 0.70 | 1.0 (0.7–1.5) | 0.90 | 1.0 (0.7–1.5) | 0.83 |
> 35 | 0.6 (0.3–1.3) | 0.21 | 0.7 (0.4–1.4) | 0.31 | 0.7 (0.4–1.4) | 0.35 |
Females | 0.7 (0.6–0.9) | 0.006 | 0.8 (0.6–1.1) | 0.10 | 0.8 (0.6–1.0) | 0.09 |
Chronic cardiac failure history | 0.6 (0.3–1.2) | 0.13 | 0.4 (0.2–0.9) | 0.018 | 0.4 (0.2–0.8) | 0.007 |
Cerebral stroke | 0.8 (0.4–1.8) | 0.58 | 0.6 (0.3–1.5) | 0.31 | ||
Statins | 1.1 (0.7–1.7) | 0.69 | 1.0 (0.7–1.6) | 0.93 | ||
Antiplatelet agents | 1.0 (0.6–1.5) | 0.82 | 0.9 (0.5–1.4) | 0.51 | ||
Smoking | 0.9 (0.7–1.2) | 0.54 | ||||
COPD | 1.4 (0.9–2.2) | 0.19 | 1.0 (0.6–1.7) | 0.97 | ||
Cancer | 1.8 (1.2–2.8) | 0.005 | 2.0 (1.2–3.4) | 0.008 | 2.0 (1.2–3.4) | 0.009 |
Familial history of VTE | 1.1 (0.8–1.5) | 0.47 | ||||
Unprovoked VTE | 1.7 (1.3–2.2) | < 0.001 | 2.1 (1.4–3.1) | 0.001 | 2.0 (1.3–3.0) | 0.001 |
OSA history | 1.5 (0.7–3.0) | 0.33 | 1.6 (0.7–3.4) | 0.26 | 1.4 (0.6–2.9) | 0.42 |
OSA occurrence | 2.8 (0.7–11.3) | 0.15 | 2.4 (0.6–9.8) | 0.23 | 2.3 (0.6–9.6) | 0.24 |
AHI | 1.0082 (0.9775–1.040) | 0.61 | ||||
AHI (continuous range of 10) | 1.1 (0.8–1.5) | 0.72 | ||||
Nocturnal desaturation (hour index) | 0.9776 (0.9080–1.052) | 0.97 | ||||
Anticoagulation duration | 0.9995 (0.9989–0.9999) | 0.54 | 0.9974 (0.9989–1.0005) | 0.52 | 0.9998 (0.999–1.0006) | 0.56 |